Patient characteristics

No. pts	213
Mean ± SD age/median (range)	66.4 ± 7.75/67.0	(46–90)
No. race (%):
Black/African American	17	(8.0)
American Indian or Alaska native	1	(0.5)
Native Hawaiian or other Pacific islander	2	(0.9)
White	188	(88)
Other	3	(1.4)
Missing	2	(0.9)
Mean ± SD mos since initial diagnosis/median (range)	70.0 ± 55.4/54.3	(4.2–270.9)
Time since adjuvant treatment:
No. pts	51
Mean ± SD mos/median (range)	38.9 ± 32.8/30.0	(3.9–171.5)
No. primary prostatectomy (%):*	164	(77)
+ Radiotherapy	43	(26)
No radiotherapy	121	(74)
No. no primary prostatectomy (%):†	49	(23)
No. Radiotherapy alone (%):	24	(49)
External beam radiotherapy only	21	(43)
Brachytherapy only	1	(2.0)
External beam radiotherapy + brachytherapy	2	(4.1)
No. primary radiotherapy ± other treatments (%):†	22	(45)
External beam radiotherapy + ADT	17	(35)
External beam radiotherapy + cryotherapy	2	(4.1)
Brachytherapy + ADT	1	(2.0)
External beam radiotherapy, brachytherapy + ADT	2	(4.1)
No. other primary treatment (%):†	3	(6.1)
Cryotherapy	1	(2.0)
High intensity focal ultrasound	1	(2.0)
High dose rate brachytherapy	1	(2.0)
Mean ± SD ng/ml PSA/median (range)	4.24 ± 10.22/1.00	(0.2–93.5)
No. Gleason score (%):‡
6 or Less	27	(13)
7	134	(63)
8 or Greater	50	(23)
Missing	2	(0.9)

^*Denominator was number of patients with prostatectomy.

^†Denominator was number of patients without prostatectomy.

^‡Data from biopsy in 183 patients and surgery in 150.